ANDA 220110, held by Aurobindo Pharma Ltd. Triamcinolone Acetonide.
As of Nov 15, 2026, ANDA 220110 (Triamcinolone Acetonide), held by Aurobindo Pharma Ltd, was first approved by FDA on Aug 11, 2026, with 0 approved supplements and 0 published complete response letters.
Uses temporarily relieves these symptoms of hay fever or other upper respiratory allergies: nasal congestion runny nose sneezing itchy nose
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 11, 2026 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Triamcinolone Acetonide0.055MG/SPRAY · spray, metered;nasal | Triamcinolone Acetonide | OTC |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
